Articles by tag: diabetes-treatment

FDA to Review Afrezza: First Needle-Free Insulin for Children

On May 29, 2026, the FDA will decide on Afrezza inhaled insulin for children aged 4–17. Learn why this is a market shift and a chance for a needle-free life. Read the analysis.

FDA to Review Inhaled Insulin Afrezza for Children

On May 29, FDA will decide on needle-free insulin Afrezza for children aged 4–17. Learn why this is a paradigm shift in diabetology. Detailed analysis in the article.

Langlara: FDA approved Chinese insulin biosimilar

FDA approved interchangeable biosimilar insulin glargine Langlara from Chinese Sunshine Lake. Learn how this will change the US market and prices for patients. Detailed analysis inside.